NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Wednesday that its second quarter revenues rose 78 percent year over year, thanks to a 59 percent increase in testing volumes for its Cologuard noninvasive colon cancer screening test.

For the three months ended June 30, the molecular diagnostics company reported revenues of $102.9 million, up from $57.6 million in Q2 2017. But the results missed analysts' average estimate of $104.7 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.